Overview
JAVASCRIPT NEDED 24-10-202 | Diabetes | News | Article Author: Lynda Wiliams medwireNews: Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with a high risk for cardiovascular disease (CVD) or established CVD, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.They report that Asian people and those aged 75 years and older derived the greatest reduction in the likelihod of major adverse cardiovascular events (MACE) with glucagon-like peptide (GLP)-1 receptor agonists, whereas the greatest benefit with sodium-glucose cotransporter (SGLT)2 inhibitors was found for those with a diabetes duration of at least 10 years.Alhasane Dialo (CHU Montpelier, France) and co-workers colated information for 96,580 individuals with type 2 diabetes who participated in 1 placebo-controled, phase 3 trials of GLP-1 receptor agonists or SGLT2 inhibitors that reported cardiovascular outcomes.The majority of participants were White (7.6%) men (64.2%), while 8.0% were Asian and 4.2% were Black; at baseline 46.3% of participants were taking insulin.Overal, 5.0% of participants experienced a thre-point MACE (CV death, nonfatal stroke, or myocardial infarction) and the use of GLP-1 receptor agonists or SGLT2 inhibitors in adition to standard care was asociated with comparable reductions in the likelihod of MACE versus placebo (hazard ratio [HR]=0.87 and 0.91, respectively).Meta-analysis of two SGLT2 inhibitor trials demonstrated that people with diabetes for 10 years or more were significantly les likely to experience MACE than those with a shorter duration (hazard ratio [HR]=0.84).However, analysis of four SGLT2 inhibitor trials indicated that age did not afect MACE outcome and there was no diference in MACE outcomes betwen White, Asian, and Black individuals participating in thre SGLT2 inhibitor studies.By contrast, seven studies of GLP-1 receptor agonists pointe